All Vaccinology articles
-
NewsMOPEVACLAS vaccine candidate for Lassa fever enters clinical trials
After more than 20 years of research on arenaviruses, researchers have developed an original vaccine platform known as MOPEVAC. A Phase Ia clinical trial is set to begin for the platform’s first vaccine candidate, which targets Lassa fever, a hemorrhagic fever responsible for thousands of deaths worldwide each year.
-
NewsmRNA-based COVID-19 vaccines train the ‘long-term memory’ of the innate immune system
A study showed that vaccination of multiple mRNA-based COVID-19 vaccines could induce persistent epigenetic changes in innate immune cells, leading to long-term immune responses for SARS-CoV-2 and other pathogens.
-
News‘It’s a shot, not a vaccine like MMR’: New skepticism prompts call for action
This ‘vaccine is not a vaccine’ is a new, previously unreported type of vaccine-specific scepticism, and it arose only during the COVID-19 pandemic. However, it might, according to the researchers, also apply to the flu vaccine.
-
NewsHow Zika virus knocks out our immune defenses
Scientists have made striking discoveries regarding the different infection mechanisms of Zika and dengue virus of the same viral family. These understandings pave the way for vaccine development to combat flaviviruses with similarities.
-
NewsMeasles elimination versus eradication: The difference explained
As of March 13, the CDC has confirmed 301 cases of measles as well as the death of a child in Texas. Amira Roess, an epidemiologist and professor of global health, clarifies the benefits of vaccinating children and adolescents against measles.
-
NewsNewer hepatitis B vaccine shows promise as booster for health care workers
A new study compares the effectiveness of Heplisav-B, a new hepatitis vaccine, vs. standard hepatitis B vaccines as a booster in previously vaccinated individuals.
-
News‘Low-sugar’ vaccine can provide broad immunity against coronavirus variants
A universal vaccine for coronaviruses removes sugar molecules from an area of a coronavirus spike protein that rarely mutates and creates effective and plentiful antibodies to inactivate the virus.
-
NewsH5N1 influenza viral lineages beginning to evade human immunological defenses
A new computer modelling approach predicts the protein-antibody interactions of the potentially pandemic-causing H5N1 avian influenza virus lineage. It helps to understand the viral evolution to ensure high vaccine efficacy.
-
NewsStudy yields new data on Mpox vaccine effectiveness in people with HIV
A new study has found that a single dose of the Imvanex vaccine provides protection against Mpox with 84% effectiveness. For people with HIV, however, a single dose of the vaccine fails to offer sufficient protection. All at-risk groups, especially people with HIV, should receive the second dose of the vaccine as recommended.
-
NewsLead science organizations affirm vaccine safety amid rising misinformation and declining trust
A unified statement, issued by a coalition of leading scientific and medical organizations, addresses the rise in vaccine misinformation and a decline in trust of science, amidst the outbreaks of preventible infectious diseases. It reassures the current concerns on vaccine safety and emphasizes the importance of vaccinations in public health.
-
NewsNIH-sponsored trial of Lassa vaccine opens
A National Institutes of Health (NIH)-sponsored clinical trial of a candidate vaccine to prevent Lassa fever has begun enrolling participants at the University of Maryland School of Medicine, Baltimore.
-
NewsStudy finds new targets needed for vaccine to prevent herpesvirus transmission to babies
Despite the lack of research on vaccines against congenital cytomegalovirus (CMV), a research has recently discovered that the virus is able to cause cross-placental transmission even with the absence of multple essential proteins, providing insights for future vaccine development.
-
NewsA review of Clostridioides difficile infection and treatments
<i>Clostridioides difficile</i> is a serious nosocomial infection that could cause from mild diarrhea to fatal colitis. Here presents a general overview that describes the current and emerging treatment practices for the prevention of <i>Clostridioides difficile</i> infection and its recourrences.
-
NewsOlder adults might be more resistant to bird flu infections than children
Previous exposures to seasonal flu strains could prime the immune system to produce antibodies against the current version of H5N1 avian influenza virus in older adults, whilst children would benefit more from H5N1 vaccinations.
-
NewsThe relationship between gut microbiota, immunoglobulin A, and vaccine efficacy
Researchers concluded that the close relationship between immunoglobulin A (IgA) deficiency and the gut microbiota overgrowth is closely tied with the pneumococcal vaccine effectiveness in adults, thus providing insights for preventative strategies to enhance the vaccine response.
-
NewsMeasles on the rise again in Europe: Time to check your vaccination status
Eight out of ten people who were diagnosed with measles in the EU/EEA in the last year were not vaccinated, according to a new measles and rubella update.
-
NewsResearchers announce breakthrough in next-generation polio vaccines
Researchers have taken a major step towards producing a more affordable and lower-risk polio vaccine using virus-like particles (VLPs). These particles mimic the outer protein shell of poliovirus, but are empty inside.
-
NewsMeningococcal vaccine found to be safe and effective for infants in sub-Saharan Africa
A new global health study found a vaccine that protects against five strains of meningitis prevalent in sub-Saharan Africa is safe and effective for use in young children beginning at 9 months of age.
-
NewsMulti-dose vaccines administered in the same site boost immune response
New research suggests that receiving multiple doses of a vaccine in the same limb leads to faster antibody development, an important strategy for providing immunity as quickly as possible during a pandemic or disease outbreak.
-
NewsInhaled COVID vaccine study begins recruitment for phase-2 human trials
Researchers have started a phase-2 clinical trial on a next-generation, inhaled COVID-19 vaccine. Findings from the phase-1 trial indicate that the vaccine is more effective at inducing immune responses than traditional injected vaccines are.